Cargando…

Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue

Molecular drugs targeting mutated or rearranged oncogene drivers have become one of the standard recognized treatments in patients with advanced and recurrent non-small cell lung cancer. RET is located in the long arm of human chromosome 10 and encodes a receptor tyrosine kinase protein, and RET fus...

Descripción completa

Detalles Bibliográficos
Autores principales: Takamori, Shinkichi, Matsubara, Taichi, Haratake, Naoki, Toyokawa, Gouji, Fujishita, Takatoshi, Toyozawa, Ryo, Ito, Kensaku, Yamaguchi, Masafumi, Taguchi, Kenichi, Okamoto, Tatsuro, Seto, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419300/
https://www.ncbi.nlm.nih.gov/pubmed/34497761
http://dx.doi.org/10.3389/fonc.2021.704084
_version_ 1783748719856844800
author Takamori, Shinkichi
Matsubara, Taichi
Haratake, Naoki
Toyokawa, Gouji
Fujishita, Takatoshi
Toyozawa, Ryo
Ito, Kensaku
Yamaguchi, Masafumi
Taguchi, Kenichi
Okamoto, Tatsuro
Seto, Takashi
author_facet Takamori, Shinkichi
Matsubara, Taichi
Haratake, Naoki
Toyokawa, Gouji
Fujishita, Takatoshi
Toyozawa, Ryo
Ito, Kensaku
Yamaguchi, Masafumi
Taguchi, Kenichi
Okamoto, Tatsuro
Seto, Takashi
author_sort Takamori, Shinkichi
collection PubMed
description Molecular drugs targeting mutated or rearranged oncogene drivers have become one of the standard recognized treatments in patients with advanced and recurrent non-small cell lung cancer. RET is located in the long arm of human chromosome 10 and encodes a receptor tyrosine kinase protein, and RET fusion-positive lung adenocarcinoma occurs in 1%–2% of cases. Clinical trials of multikinase inhibitors, including cabozantinib, vandetanib, sorafenib, and lenvatinib, that inhibit RET oncogene activity have shown their antitumor efficacy. Recently, RET inhibitors such as pralsetinib and selpercatinib that are specialized for RET kinase have also been developed, and their efficacy was investigated in previous clinical trials (BLU-667 and LOXO-292). In this review, we summarized the effects and adverse events of multikinase and selective RET inhibitors and the various diagnostic techniques for RET gene fusion. In the perspective part, we focused on the unsolved issues on treatment for RET fusion-positive lung cancer and future developments.
format Online
Article
Text
id pubmed-8419300
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-84193002021-09-07 Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue Takamori, Shinkichi Matsubara, Taichi Haratake, Naoki Toyokawa, Gouji Fujishita, Takatoshi Toyozawa, Ryo Ito, Kensaku Yamaguchi, Masafumi Taguchi, Kenichi Okamoto, Tatsuro Seto, Takashi Front Oncol Oncology Molecular drugs targeting mutated or rearranged oncogene drivers have become one of the standard recognized treatments in patients with advanced and recurrent non-small cell lung cancer. RET is located in the long arm of human chromosome 10 and encodes a receptor tyrosine kinase protein, and RET fusion-positive lung adenocarcinoma occurs in 1%–2% of cases. Clinical trials of multikinase inhibitors, including cabozantinib, vandetanib, sorafenib, and lenvatinib, that inhibit RET oncogene activity have shown their antitumor efficacy. Recently, RET inhibitors such as pralsetinib and selpercatinib that are specialized for RET kinase have also been developed, and their efficacy was investigated in previous clinical trials (BLU-667 and LOXO-292). In this review, we summarized the effects and adverse events of multikinase and selective RET inhibitors and the various diagnostic techniques for RET gene fusion. In the perspective part, we focused on the unsolved issues on treatment for RET fusion-positive lung cancer and future developments. Frontiers Media S.A. 2021-08-23 /pmc/articles/PMC8419300/ /pubmed/34497761 http://dx.doi.org/10.3389/fonc.2021.704084 Text en Copyright © 2021 Takamori, Matsubara, Haratake, Toyokawa, Fujishita, Toyozawa, Ito, Yamaguchi, Taguchi, Okamoto and Seto https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Takamori, Shinkichi
Matsubara, Taichi
Haratake, Naoki
Toyokawa, Gouji
Fujishita, Takatoshi
Toyozawa, Ryo
Ito, Kensaku
Yamaguchi, Masafumi
Taguchi, Kenichi
Okamoto, Tatsuro
Seto, Takashi
Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue
title Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue
title_full Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue
title_fullStr Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue
title_full_unstemmed Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue
title_short Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue
title_sort targeted therapy for ret fusion lung cancer: breakthrough and unresolved issue
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419300/
https://www.ncbi.nlm.nih.gov/pubmed/34497761
http://dx.doi.org/10.3389/fonc.2021.704084
work_keys_str_mv AT takamorishinkichi targetedtherapyforretfusionlungcancerbreakthroughandunresolvedissue
AT matsubarataichi targetedtherapyforretfusionlungcancerbreakthroughandunresolvedissue
AT haratakenaoki targetedtherapyforretfusionlungcancerbreakthroughandunresolvedissue
AT toyokawagouji targetedtherapyforretfusionlungcancerbreakthroughandunresolvedissue
AT fujishitatakatoshi targetedtherapyforretfusionlungcancerbreakthroughandunresolvedissue
AT toyozawaryo targetedtherapyforretfusionlungcancerbreakthroughandunresolvedissue
AT itokensaku targetedtherapyforretfusionlungcancerbreakthroughandunresolvedissue
AT yamaguchimasafumi targetedtherapyforretfusionlungcancerbreakthroughandunresolvedissue
AT taguchikenichi targetedtherapyforretfusionlungcancerbreakthroughandunresolvedissue
AT okamototatsuro targetedtherapyforretfusionlungcancerbreakthroughandunresolvedissue
AT setotakashi targetedtherapyforretfusionlungcancerbreakthroughandunresolvedissue